A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease
Eisai Co., Ltd.
To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of
E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux
disease in a multicenter, randomized, double-blind, comparative study.
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
To investigate esophageal reflux condition in patients with non-erosive gastroesophageal
reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week
treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.